BABA vs RECT

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

RECT exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a conservative Debt/Equity ratio of 0.35. The stock is significantly undervalued, trading at $1.62 against a Graham Number of $2.57 and an intrinsic value of $5.90. Despite a devastating one-year price decline of 59.4%, explosive earnings growth (125% YoY) and a recent short-term price recovery suggest a potential value reversal. The company significantly outperforms sector averages in profitability and leverage, though it remains a high-risk micro-cap.